Available through:

503A Pharmacy

Estradiol Patch

This product is available solely through our 503A Compounding Pharmacy, ensuring personalized care and precision in every order. Please note that a valid prescription is required for purchase. If you do not have an account, please contact us.

See Product Details

Start your order

Product Overview

The estradiol patch is a single-use matrix transdermal system engineered to deliver a steady dose of synthetic 17-β estradiol through the dermis and directly into the systemic circulation over several days, typically with patch replacement once or twice weekly depending on the prescribed regimen and product strength.

By bypassing the gastrointestinal tract and first-pass hepatic metabolism, the system supports lower peak-to-trough fluctuations in serum estrogen concentration than oral formulations while maintaining clinically relevant exposure equivalent to endogenous levels observed during the early-to-mid follicular phase of the menstrual cycle.

Commercially marketed dosage strengths-0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day-are achieved by altering the surface area of the adhesive polymer that contains the active hormone dispersed in an acrylate matrix; each system is supplied in an individually sealed pouch to preserve potency until use.

Within 8-12 hours of initial application, estradiol serum concentrations reach near-steady-state and remain relatively constant for up to 84 hours, after which the exhausted system is removed and replaced at an alternate skin site to minimize local irritation.

The patch is prescription-only and, when compounded by a 503A pharmacy, is prepared for a specific patient in compliance with United States Pharmacopeia standards.^[1]

In clinical practice the transdermal estradiol system is most often prescribed for the treatment of moderate to severe vasomotor symptoms such as hot flashes and night sweats, for the prevention of postmenopausal osteoporosis in women at significant fracture risk who cannot tolerate or have contraindications to alternative therapies, and as replacement therapy in individuals with primary ovarian insufficiency or oophorectomy where endogenous estrogen is deficient.

Because estrogen monotherapy in patients with an intact uterus can unopposedly stimulate the endometrium, guidelines generally recommend the concomitant use of a progestogen or a levonorgestrel-containing patch unless hysterectomy has been performed.

Dosage should be the lowest that effectively mitigates symptoms, with reassessment at three- to six-month intervals to consider tapering or discontinuation.

Unlike oral agents, the patch produces minimal stimulation of hepatic protein synthesis, thereby potentially reducing the magnitude of sex-hormone-binding globulin induction, triglyceride elevation, and clotting factor synthesis; however, systemic exposure is sufficient to necessitate the same cardiovascular and oncologic precautions applied to all systemic estrogen therapies.^[2]

17-β Estradiol, the principal bioactive estrogen in humans, exerts its pharmacological action primarily through high-affinity binding to nuclear estrogen receptors α and β located in reproductive tissues, bone, vasculature, and the central nervous system.

Ligand binding triggers receptor dimerization and recruitment to estrogen response elements on chromatin, modulating transcription of genes involved in calcium homeostasis, lipid metabolism, endothelial nitric-oxide synthase expression, and serotonergic signaling.

The resulting downstream effects include decreased osteoclast-mediated bone resorption, improved low-density lipoprotein clearance, and modulation of hypothalamic thermoregulatory centers, translating to clinical relief of vasomotor instability.

Estradiol also activates membrane-associated G-protein-coupled estrogen receptor pathways that contribute to rapid kinase cascades promoting vasodilation and neuroprotection.

Transdermally delivered estradiol achieves estrone-to-estradiol ratios closer to premenopausal physiology than oral estrogen because the liver is not the first site of exposure, thereby preserving the endocrine milieu necessary for optimal receptor signaling.^[3]

Pharmacokinetic comparisons demonstrate that transdermal administration produces circadian profiles with significantly lower peak levels and narrower fluctuation indices than oral dosing, an effect that may translate into fewer estrogen-related adverse events such as nausea or headache and a smaller impact on coagulation factor activation.

Reviews evaluating randomized and observational data in postmenopausal cohorts also note that the patch’s avoidance of the gut-liver axis limits estrogen-induced increases in C-reactive protein and thrombin generation, though absolute risk reduction for thrombosis remains modest and patient-specific variables such as obesity, genetic thrombophilia, and concomitant medication use remain decisive.

Additionally, steady dermal uptake allows clinicians to titrate exposure by adjusting patch surface area rather than altering dose frequency, a feature especially advantageous in individuals with erratic gastrointestinal absorption secondary to bariatric surgery or inflammatory bowel disease.

Despite these pharmacologic benefits, the mechanistic pathways engaged are fundamentally the same as those activated by endogenous hormone, and potential stimulation of estrogen-responsive neoplasms is not eliminated; thus, comprehensive risk assessment remains essential.^[4]

Systemic estradiol therapy is contraindicated in patients with unexplained vaginal bleeding, active or history of estrogen-dependent malignancies such as breast carcinoma, active deep-vein thrombosis or pulmonary embolism, and in those with known hereditary or acquired thrombophilias because of the heightened pro-coagulant milieu engendered by estrogen exposure.

Additional absolute contraindications include active arterial thromboembolic disease, severe hepatic dysfunction, and hypersensitivity to any component of the patch matrix; relative contraindications encompass controlled hypertension, migraine with aura, gallbladder disease, and familial hypertriglyceridemia.

Because transdermal delivery does not abrogate estrogen’s proliferative effect on endometrial tissue, unopposed use in women with an intact uterus carries a documented risk of endometrial carcinoma, necessitating concomitant progestogen protection or endometrial surveillance.

Finally, estrogen monotherapy is not indicated as primary or secondary prevention for cardiovascular disease or dementia, and it should not be employed for weight management or athletic performance enhancement.^[5]

Boxed safety statements highlight additional populations for whom estradiol therapy must be avoided, including pregnant individuals, women with active systemic lupus erythematosus experiencing vascular flares, and patients with protein C, protein S, or antithrombin deficiencies that potentiate thrombosis.

Case reports describe acceleration of hepatic adenoma growth under estrogen influence, and clinicians are advised to discontinue treatment at the earliest sign of cholestatic jaundice or markedly elevated triglycerides.

Estradiol can exacerbate hereditary angioedema by augmenting hepatic synthesis of one chain of C1 esterase inhibitor, and caution is appropriate in women with asthma, epilepsy, or porphyria where hormonal variations may alter disease control.

Because estrogen can increase thyroid-binding globulin, individuals on levothyroxine therapy require monitoring for altered thyroid-stimulating hormone values.

Appropriate baseline evaluation, including blood pressure measurement, mammography, and assessment of cardiovascular risk, therefore precedes initiation of transdermal estradiol in all candidates.^[6]

Clinically relevant pharmacokinetic interactions arise predominantly through cytochrome P450 3A4 modulation, as estradiol is extensively metabolized by this hepatic isoenzyme.^[7]

Potent inducers such as rifampin, carbamazepine, phenytoin, and St. John’s wort can lower circulating estradiol concentrations and compromise symptom control, whereas inhibitors including ketoconazole, clarithromycin, grapefruit juice constituents, and ritonavir can elevate hormone levels, theoretically enhancing the likelihood of adverse events like breast tenderness or thromboembolism.

Estradiol may antagonize lamotrigine by accelerating glucuronidation, potentially reducing seizure control, and observational data suggest that co-administration with levothyroxine may necessitate dose adjustment because of increased thyroxine-binding globulin synthesis.

Oral anticoagulants such as warfarin can exhibit variable international normalized ratio alterations, prompting closer monitoring during therapy initiation or dose changes.^[7]

Pharmacodynamic interactions warrant equal attention; selective estrogen receptor modulators, aromatase inhibitors, ospemifene, or fulvestrant can blunt or counteract estradiol’s therapeutic goals, yet simultaneous use is occasionally encountered in complex oncologic settings and requires multidisciplinary coordination.

Alcohol consumption may increase free estradiol fractions, while tobacco smoking induces CYP1A2 and synergistically augments estrogen-mediated thrombotic risk, particularly in women over thirty-five.

Concomitant corticosteroid use can precipitate fluid retention, and the patch should be discontinued at least four to six weeks before elective surgeries with prolonged immobilization to minimize perioperative clot risk.

Because estradiol may interfere with certain laboratory assays, clinicians should inform diagnostic laboratories when high-performance liquid chromatography or immunoassay hormone panels are ordered during therapy.^[8]

Can I cut a patch in half if my practitioner recommends a dose reduction?
Standard labeling discourages altering the system, but laboratory analyses show that certain matrix patches maintain content uniformity when divided diagonally, provided the cut portion is stored airtight and used within one month; nevertheless, any modification should occur only under explicit professional guidance.^[14]

Does cutting the patch change drug stability?
Data from a clinical endocrine study examining pubertal induction found no significant decline in estradiol concentration for matrix pieces stored at 21 °C for up to thirty days, supporting chemical stability when the matrix is evenly split and re-sealed.^[15]

Should unused patches be kept in the bathroom cabinet?
Humid environments accelerate adhesive degradation; guidelines recommend room-temperature storage in the original foil pouch away from moisture-rich settings such as bathrooms or kitchen sinks.^[17]

Why must the application site be rotated each time?
Rotating between lower abdomen and buttocks prevents cumulative dermal irritation and maintains consistent absorption, as cross-over studies confirm variability in flux if consecutive systems are placed on the same area.^[1]

Can the estradiol patch be worn together with oral progesterone instead of a combination patch?
Randomized trials involving oral progesterone co-therapy report effective vasomotor symptom control and adequate endometrial protection, validating this strategy when a levonorgestrel-containing patch is not tolerated.^[19]

Is a lower-dose patch as effective as higher strengths?
Clinical dose-finding work with estradiol matrix systems showed that even the 0.025 mg/day patch significantly reduced hot-flash frequency, though higher dosages produced incremental benefit; clinicians therefore start low and titrate based on individual response.^[20]

Does the patch still need to be stopped before major surgery?
Guidance for combined estradiol-levonorgestrel systems recommends discontinuation four to six weeks before elective procedures requiring prolonged immobilization to mitigate venous thromboembolic risk, a precaution generally extended to estradiol-only patches.^[21]

How should used patches be thrown away safely?
After folding the adhesive sides together, spent systems should be placed in a sturdy, child-resistant container with household trash; flushing or discarding where children or pets can access them is contraindicated due to residual hormone content.^[22]

What if a patch is briefly exposed to temperatures above 30 °C, such as in a parked car?
Occasional short exposures are unlikely to cause dose dumping, yet repeated excursions above recommended storage limits can weaken the adhesive and alter release kinetics, so replacement is advised if the backing puckers or no longer adheres well.^[23]

Disclaimer: This compounded medication is prepared under section 503A of the U.S. Federal Food, Drug, and Cosmetic Act. Safety and efficacy for this formulation have not been evaluated by the FDA. Therapy should be initiated and monitored only by qualified healthcare professionals.

503A vs 503B

503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider.
503B outsourcing facilities compound products on a larger scale (bulk amounts) for healthcare providers to have on hand and administer to patients in their offices.

Learn More